Peptide Comparison
Tesamorelin vs MK-677
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Tesamorelin has stronger documented evidence (FDA-Approved) than MK-677 (Phase 3 (not approved)) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, Tesamorelin is the safer pick. MK-677 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Tesamorelin | MK-677 | |
|---|---|---|
| Class | GHRH analog (FDA-approved) | Oral non-peptide ghrelin receptor agonist |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion | GHS-R1a agonist; stimulates pulsatile GH/IGF-1 release; orally bioavailable spiropiperidine |
| Route | SC injection | Oral |
| Half-life | ~26 min | ~24 hrs |
| Dosage (research) | 2 mg SC daily (FDA label) | 12.5 mg oral daily (community starting dose to mitigate water retention and appetite increase, escalate to label dose 25 mg/day per MK-0677-014 Phase 3 protocol) |
| Evidence tier | FDA-Approved | Phase 3 (not approved) |
| Research depth | 127 indexed | 120 indexed |
| Availability | Prescription | Research Chemical |
| Reported risks | Injection site reactions; hyperglycemia; joint pain; edema; elevated IGF-1 | Increased hunger; water retention; insulin resistance risk; lethargy; CHF risk (elderly trials) |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Tesamorelin or MK-677?
Tesamorelin has stronger documented evidence (FDA-Approved) than MK-677 (Phase 3 (not approved)) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, Tesamorelin is the safer pick. MK-677 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between Tesamorelin and MK-677?
Tesamorelin is classed as GHRH analog (FDA-approved); MK-677 is classed as Oral non-peptide ghrelin receptor agonist. Reported mechanism: Tesamorelin, Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion; MK-677, GHS-R1a agonist; stimulates pulsatile GH/IGF-1 release; orally bioavailable spiropiperidine. Reported half-life: Tesamorelin, ~26 min; MK-677, ~24 hrs. Routes in published studies: Tesamorelin, SC injection; MK-677, Oral.
Which has stronger evidence, Tesamorelin or MK-677?
Tesamorelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Tesamorelin is graded FDA-Approved, with 13 cited sources on its reference page and 127 indexed studies. MK-677 is graded Phase 3 (not approved), with 5 cited sources on its reference page and 120 indexed studies.
Which is more accessible, Tesamorelin or MK-677?
Tesamorelin is FDA-approved and MK-677 is not. Catalog status: Tesamorelin, Prescription; MK-677, Research Chemical. FDA lists MK-677 in category 2 of its bulk-substance compounding policy (503A; 503B, added 503A: September 29, 2023 503B: December 29, 2022).
Are Tesamorelin and MK-677 ever combined?
Tesamorelin and MK-677 appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…